

Patient Alert Card

Apixaban

Carry this card with you all times

Show this card to your pharmacist, dentist and any other healthcare professionals that treat you.

Information for patients

- ◆ Take Apixaban SPC® regularly as instructed. If you miss a dose, take it as soon as you remember and continue to follow your dosing schedule.
- ◆ Do not stop taking Apixaban SPC® without talking to your doctor, as you are at risk of suffering from a stroke or other complications.
- ◆ Apixaban SPC® helps to thin your blood. However, this may increase your risk of bleeding.
- ◆ Signs and symptoms of bleeding include bruising or bleeding under the skin, tar-colored stools, blood in urine, nose-bleed, dizziness, tiredness, paleness or weakness, sudden severe headache, coughing up blood or vomiting blood
- ◆ If the bleeding does not stop on its own, seek medical attention immediately.
- ◆ If you need surgery, inform your doctor that you are taking Apixaban SPC®.



This document has been reviewed and approved by Saudi Food and Drug Authority (SFDA)

Version 1.0
Date: 12.2020

I am under anticoagulation treatment with Apixaban to prevent blood clots

Information for healthcare professionals

- ◆ Apixaban SPC® is an oral anticoagulant acting by direct selective inhibition of factor Xa.
- ◆ Apixaban SPC® may increase the risk of bleeding. In case of major bleeding events, it should be stopped immediately.
- ◆ Treatment with Apixaban SPC® does not require routine monitoring of exposure. A calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations, e.g., overdose and emergency surgery (prothrombin time (PT), international normalized ratio (INR) and activated partial thromboplastin time (aPTT) clotting tests are not recommended) - see SmPC.
- ◆ An agent to reverse the anti-factor Xa activity of apixaban is available.

Please fill the below section or ask your Doctor to do it

Name: _____

Date of Birth: _____

Indication: _____

Dose: _____ mg twice Daily

Doctor's name: _____

Doctor's Telephone: _____



This document has been reviewed and approved by Saudi
Food and Drug Authority (SFDA)

Version 1.0
Date: 12.2020